维立志博注射用LBL - 024启动Ib/Ⅱ期临床 适应症为卵巢癌

新浪财经
Sep 22, 2025

药物临床试验登记与信息公示平台数据显示,南京维立志博生物科技股份有限公司的评价LBL - 024联合紫杉醇注射液治疗铂耐药卵巢癌患者的有效性和安全性的开放、多中心Ib/Ⅱ期临床研究已启动。临床试验登记号为CTR20253674,首次公示信息日期为2025年9月22日。该药物剂型为注射液,规格为100mg/瓶,用法用量按方案规定使用。本次试验Ib期主要目的为评价LBL - 024联合紫杉醇注射液治疗...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10